The table below shows NEUROCRINE BIOSCIENCES INC's cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
$145.80M
$64.80M
$130.30M
-$125.20M
-$40.50M
$87.30M
Capital expenditure
$9.10M
$10.70M
$11.20M
$8.50M
$7.60M
$4.50M
Investing cash flow
-$506.20M
$14.20M
-$55.00M
-$42.10M
-$31.60M
$63.10M
Dividends paid
-
-
-
-
NBIX operating cash flow (10-K history)
NEUROCRINE BIOSCIENCES INC reported operating cash flow of $782.70M for fiscal year 2025. That is up 31.5% from $595.40M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from -$106.18M (FY 2016) to $782.70M. Figures come from the company's audited annual reports as filed with the SEC.